Continuous use of metformin in patients receiving contrast medium: what is the evidence? A systematic review and meta-analysis.
Ting-Wan KaoKuo-Hua LeeWing P ChanKang-Chih FanChe-Wei LiuYu-Chen HuangPublished in: European radiology (2021)
There is no need to discontinue metformin either before or after intravenous contrast medium exposure in patients with eGFR > 30 mL/min/1.73 m2. In patients receiving intra-arterial contrast medium with first-pass renal exposure, there is no need to withhold metformin if eGFR is above 60 mL/min/1.73 m2. For patients who have an eGFR level between 30 and 60 mL/min/1.73 m2 and are receiving intra-arterial contrast medium with first-pass renal exposure, no case of lactic acidosis was observed based on present data, but further evidence is needed to make a strong suggestion regarding its safety.
Keyphrases
- small cell lung cancer
- magnetic resonance
- epidermal growth factor receptor
- tyrosine kinase
- end stage renal disease
- contrast enhanced
- ejection fraction
- chronic kidney disease
- newly diagnosed
- magnetic resonance imaging
- peritoneal dialysis
- prognostic factors
- computed tomography
- electronic health record
- deep learning
- patient reported outcomes
- artificial intelligence
- patient reported